|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||14.22 - 14.89|
|52 Week Range||8.31 - 32.74|
|PE Ratio (TTM)||-3.54|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
For his "Executive Decision" segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant
The manufacturing issues that the company was facing were connected to an investigation by the U.S. Food and Drug Administration (FDA). Valeant Pharmaceuticals Intl Inc notes that the FDA is planning to give the facility a Voluntary Action Indicated VAI classification. Valeant Pharmaceuticals Intl Inc says that the VAI classification will prevent manufacturing issues that further regulator actions could have caused.
Shares of Valeant Pharmaceuticals International (VRX) have tumbled 14% in August as concerns about generic drugs following Teva Pharmaceutical Industries' (TEVA) earnings sparked a specialty-pharmaceutical stock selloff. Valeant, however, is trying to make back some of those losses this week, with the stock up more than 2% today after the company announced that it was close to fixing problems at a Bausch & Lomb plant. While this might seem like a minor piece of news, it has big implications for Valeant's stock.